Metsera, Inc. MTSR

Obesity drug developer Metsera sets terms for $275M IPO
Val Brickates Kennedy
Initial public offering hologram, night panoramic city view of Bangkok. The financial center for multinational corporations in Asia. The concept of boosting the growth by IPO process. Double exposure.
2d illustrations and photos/iStock via Getty Images
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering.

In a recent SEC filing, Metsera (MTSR) said it was looking to offer 17.2M shares priced between $15

Symbol Last Price % Chg
MTSR - -
Metsera, Inc.